Timestechpharma

Macular Degeneration Treatment Market is Thriving Worldwide? Key Players Involved in the study: GlaxoSmithKline plc, Novartis AG, Bayer AG, Neurotech Pharmaceuticals, Inc., and Others

Press release   •   Jan 13, 2020 01:19 EST

The global Macular Degeneration Treatment Market is estimated to grow at CAGR above 6.6% over the forecast time frame 2018-2027 and reach the market value around $11.4 billion by 2027. The report is titled “Macular Degeneration Treatment Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 – 2027” and it intends to offer a comprehensive overview of the market to its stakeholders.

To keep pace with the increasing demand, the leading organizations are investing in various research and development initiatives. This, coupled with government support, implementation of policies supporting expansion of pharmaceutical and healthcare industries, and accessibility to improved reimbursement policies are supporting the growth of this market.

The report offers a bird’s eye view of the Macular Degeneration Treatment Market, gauging its growth trajectory over the years. It presents insights into key factors boosting the markets, besides the ones restricting its growth. The report also highlights hidden opportunities for the market besides revealing the key restraints. It is therefore intended to help market players determine their growth strategies and make informed decisions pertaining to potential investments.

Download Free Sample Report Pages@ https://www.acumenresearchandconsulting.com/request-sample/1203

The report includes information obtained from various sources from within the industry. Latest statistics from international organizations are considered while compiling this study. In addition to this, opinions from experts are taken to offer refined growth forecasts. Information compiled in the study is derived with primary and secondary research methods. Besides this, industry-leading analytical tools are used examine information received. The report uses price trend analysis, qualitative and quantitative analysis to evaluate prevalent market trends.

Scope of the Report:

The report first uses historic data from different companies. The data collected is used to analyses the growth of industries in the past years. It includes data from the year 2015 to the year 2018. The forecast data provides the reader with an understating of the future of the market. The same data is used to predict the expectation of the companies and how they are expected to evolve in the coming years. The research provides historical as well as estimated data from the year 2018 to 2027. The details in the report give a brief overview of the market by examining its historical data, the current data, and forecast data to understand the growth of the market.

Competitive Landscape

The competition witnessed in the market is soaring. With rising demand for innovation, players are experimenting with various strategies to gain competitive edge and strengthen their foothold in the market. Several companies operating in the industry are looking at expanding their footprint across emerging nations to capitalize on the prevailing opportunities there. The gap in demand and supply of healthcare facilities in underdeveloped countries has resulted in the presence of unmet demand in these countries. These companies are looking at capitalizing on this to emerge at the fore of the global market.

Growth strategies adopted by the companies operating in the market are examined in detail. This is done to study how these strategies influence on this market. Furthermore, the bargaining power of suppliers and buyers. Furthermore, it reveals threat from new entrants and available substitute products.

List of Companies

The report lists down some of the leading companies operating in this market. The market share of the global Macular Degeneration Treatment Market is dominated by companies like GlaxoSmithKline plc, Novartis AG, Bayer AG, Neurotech Pharmaceuticals, Inc., Ophthotech Corporation, F. Hoffmann-La Roche Ltd., StemCells Inc., Pfizer, Inc., Sanofi, Santen Pharmaceuticals, Allergan, Inc., and Valeant Pharmaceuticals etc.

The policies adopted by these companies are studied in detail. Furthermore, the report offers insights into their product portfolio, pricing strategies, strategic collaborations, mergers and acquisitions, among others.

SWOT Analysis is conducted on the companies listed to study their strengths and weaknesses. Furthermore, the analysis offered insights into opportunities and threats present in the market for these companies. A comparative analysis between these companies is intended to highlight the most successful strategies adopted by these companies. Doing so, the report offers recommendations for growth to companies operating in the market. It is thus conducted to help companies, irrespective of their size, access relevant information.

Regional Outlook

The report segments the global Macular Degeneration Treatment Market into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa in terms of region. According to studies, developed economies are likely to offer stability to the market. The higher rate of adoption of latest technologies and the presence of a sophisticated healthcare network will augment growth in the market in North America. In Europe as well the market will gain from favourable government policies.

In the last couple of years, the investment towards expanding healthcare infrastructure has greatly surged in emerging economies of Asia Pacific and Latin America. This, coupled with the rising awareness about various diseases and the treatment available for the same will support growth in emerging countries.

Key Segments

The report segments the market into various categories. The leading segments within each category are identified in the report. Furthermore, it calculates market share that these segments hold. Factors enabling growth in this segments are studied in detail. The report also reveals the factors that may restrain the market growth in these categories.

Market Segmentation

Market By Disease Indication

  • Dry Age-related Macular Degeneration Treatment
  • Wet Age-related Macular Degeneration Treatment
  • Others

Market By Drug Class

  • Anti-vascular endothelial growth factor
  • Others

Market By End-user

  • Ambulatory Surgical Centers
  • Hospitals
  • Ophthalmic Clinics

Market Regional Analysis:

Based on the regions, the global Macular Degeneration Treatment Market is segmented into -North America (US and Canada), Europe (UK, Germany, France, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific), Latin America (Mexico, Brazil and Rest of Latin America), Middle East & Africa (GCC, South Africa and Rest of MEA).

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Macular Degeneration Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Macular Degeneration Treatment Market By Disease Indication
1.2.2.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By Disease Indication (2015-2026)
1.2.2.2. Global Macular Degeneration Treatment Market Revenue Share By Disease Indication in 2017
1.2.2.3. Dry Age-related Macular Degeneration Treatment
1.2.2.4. Wet Age-related Macular Degeneration Treatment
1.2.2.5. Others
1.2.3. Macular Degeneration Treatment Market By Drug Class
1.2.3.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.3.2. Anti-vascular endothelial growth factor
1.2.3.3. Others
1.2.4. Macular Degeneration Treatment Market By End Users
1.2.4.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By End Users (2015-2026)
1.2.4.2. Ambulatory Surgical Centers
1.2.4.3. Hospitals
1.2.4.4. Ophthalmic Clinics
1.2.5. Macular Degeneration Treatment Market by Geography
1.2.5.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Hospitals Production Date of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Macular Degeneration Treatment Major Manufacturers in 2017

CHAPTER 4. MACULAR DEGENERATION TREATMENT MARKET BY DISEASE INDICATION

4.1. Global Macular Degeneration Treatment Revenue By Disease Indication
4.2. Dry Age-related Macular Degeneration Treatment
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Wet Age-related Macular Degeneration Treatment
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Others
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. MACULAR DEGENERATION TREATMENT MARKET BY DRUG CLASS

5.1. Global Macular Degeneration Treatment Revenue By Drug Class
5.2. Anti-vascular endothelial growth factor
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Others
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. Macular Degeneration Treatment MARKET BY END USERS

6.1. Global Macular Degeneration Treatment Revenue By End Users
6.2. Ambulatory Surgical Centers
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Hospitals
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Ophthalmic Clinics
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

7.1. North America Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Macular Degeneration Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Macular Degeneration Treatment Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

8.1. Europe Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Macular Degeneration Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

9.1. Asia-Pacific Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Macular Degeneration Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

10.1. Latin America Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Macular Degeneration Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

11.1. Middle East Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Macular Degeneration Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

12.1. Africa Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Macular Degeneration Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. GlaxoSmithKline plc
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Novartis AG
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Bayer AG
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Neurotech Pharmaceuticals, Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Ophthotech Corporation
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. F. Hoffmann-La Roche Ltd.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. StemCells Inc.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Pfizer, Inc.
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Sanofi
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Santen Pharmaceuticals
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.11. Allergan, Inc.
13.11.1. Company Snapshot
13.11.2. Overview
13.11.3. Financial Overview
13.11.4. Type Portfolio
13.11.5. Key Developments
13.11.6. Strategies
13.12. Valeant Pharmaceuticals
13.12.1. Company Snapshot
13.12.2. Overview
13.12.3. Financial Overview
13.12.4. Type Portfolio
13.12.5. Key Developments
13.12.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1203

Contact Us:

Acumen Research and Consulting

Email: sales@acumenresearchandconsulting.com

Phone: +1 407 915 4157

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.